17039-Lung Cancer-NSCLC-524

Lung Cancer

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)

  • Details

ClinicalTrials.gov ID: NCT02954991
Diagnosis Type: NSCLC
USOR Number: 17039

  • Address

2800 Highway 75 North
Sherman, TX 75090
P: (903) 868-4700

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.